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Among endogenous signaling networks involved in both rewarding and homeostatic
mechanisms of obesity, a relevant role is played by the endocannabinoid (ECS) and the
opioid (EOS) systems. We here studied the transcriptional regulation of ECS and EOS
genes in the hypothalamus of Diet-induced obesity rats, a preclinical model of obesity,
as well as in humans with obesity and healthy controls. A significant and selective
increase in type 1 cannabinoid receptor gene (Cnr1) expression was observed at the
beginning of obesity development (5 weeks on high fat diet) as well as after 21 weeks
of high diet exposure. After 5 weeks on high fat diet, selective up-regulation of mu
opioid receptor gene (Oprm1) expression was also observed. Consistently, epigenetic
studies showed a selective and significant decrease in DNA methylation at specific
CpG sites at both gene promoters in overweight rats, but only after 5 weeks on
high fat diet. Moreover, significantly lower levels of DNA methylation were observed
at selected CpG sites of both receptor gene promoters, analyzed in peripheral blood
mononuclear cells from younger (<30 years old) humans with obesity, as well as in
those with shorter time length from disease onset. Taken together, we here provide
evidence of selective, synergistic and time-dependent transcriptional regulation of CNR1
and OPRM1 genes in overweight rats, as well as in human subjects. These alterations
in genes regulation could contribute to the development of the obese phenotype, and
we thus suggest CNR1 and OPRM1 epigenetic modulation as possible biomarkers of
obesity development. Due to the reversible nature of the epigenetic hallmark, our data
might also open new avenue to early environmental strategies of intervention.
Keywords: obesity, endocannabinoid system, opioid system, DNA methylation, biomarker
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INTRODUCTION
Obesity is a growing public health threat, potentially affecting
emotional, and physical health with a relevant mortality rate and
a high burden of disease for Western societies. Core symptoms
of this disease are disturbance of eating habits and inability
to control body weight, thus leading to an imbalance between
energy intake and expenditure. In recent years several approaches
have been used to treat obesity, yet the efficacy of the few
medications proven useful remains a matter of debate. Thus,
effective and safe treatments are urgently needed (Patel and
Stanford, 2018). Efforts should be made to disclose the causes
that make individuals more vulnerable to the development of
obesity, in order to gain useful information for alleviating or even
preventing occurrence of this condition. Genetic predisposition
has been implicated in disease susceptibility (Stice, 2002; Striegel-
Moore and Bulik, 2007), however, differences in phenotype
heterogeneity point also to the relevant role of the environment
and lifestyle (Hill et al., 2003). Molecular research has formed the
basis to understand how environmental factors (i.e., dieting) may
facilitate disease progression by engaging epigenetic mechanisms
(van Dijk et al., 2015), helping also to understand the increasing
epidemic of the disease in the last years within the same genome.
It is in fact well known that the latter mechanisms can evoke
transient changes (although how long they actually last is unclear)
in gene expression, involving chemical modifications of DNA
that do not affect the actual DNA sequence of the organism.
The understanding of how transcriptional regulation might affect
individual risk of developing obesity represents a major challenge
in research and may provide invaluable help for the development
of preventive strategies, or of more effective therapeutics. Central
regulation of food intake is rather complex, and thus different
endogenous key players should be considered. For instance,
it is clear that rewarding properties of food, possibly leading
to drug-like food addiction (D’Addario et al., 2014; Mancino
et al., 2015), are responsible for disease development and share
neuronal pathways that seem to overlap with drug addiction
(Volkow and Wise, 2005). These neural circuitries, driving eating
behaviors in the brain to ensure food-intake and to regulate
caloric balance, are thus controlled not only by homeostatic
mechanisms but also by reward systems to promote motivational,
hedonically driven feeding (Coccurello and Maccarrone, 2018).
Among the endogenous systems involved in both rewarding and
homeostatic mechanisms, a relevant role is played by both the
endocannabinoid (ECS) and the opioid (EOS) systems (Cota
et al., 2003a; Tanda and Goldberg, 2003), which functionally
interact with each other in mediating neurological functions
(Manzanares et al., 1999; Tanda and Goldberg, 2003). In feeding
regulation, both ECS and EOS seem to contribute to the reward
aspect of eating (Saper et al., 2002; Yeomans and Gray, 2002;
Cota et al., 2003b). Of note, several preclinical studies reported
that both opioid and cannabinoid receptor agonists stimulate
food intake (Reid, 1985; Foltin et al., 1988; Williams et al., 1998;
Glass et al., 1999; Williams and Kirkham, 1999), that is instead
reduced by antagonists (Recant et al., 1980; Marks-Kaufman
et al., 1984; Colombo et al., 1998; Di Marzo et al., 2001; Glass
et al., 2002; Hildebrandt et al., 2003; Ravinet Trillou et al., 2003;
Statnick et al., 2003; Vickers et al., 2003) with suppression of body
weight gain in rodents. It has been also observed in human trials
that opioid antagonists (naloxone, naltrexone, or nalmefene) may
be helpful in the short term to suppress appetite, even though
caution should be taken for possible long term use because of
side effects and limited weight loss (Nathan and Bullmore, 2009).
In this context, it should be recalled that rimonabant, a selective
type 1 cannabinoid receptor (CB1) antagonist able to reduce body
weight (Rinaldi-Carmona et al., 1995; Di Marzo and Despres,
2009), was an approved drug on the European market, but was
withdrawn because of an increased risk of psychiatric disorders
(Johansson et al., 2009).
Moreover, combination therapies [i.e., Contrave (Apovian
et al., 2013) and Qysmia (Gadde et al., 2011)] also held promise
for obesity treatment, and preclinical studies performed using a
combination of opioid and cannabinoid antagonists (naloxone
and nor-BNI with rimonabant) demonstrated enhanced feeding
reduction when compared to that evoked by rimonabant alone
(Lockie et al., 2011, 2015).
Against this background, the aim of this study was to advance
our knowledge about the molecular mechanisms engaging ECS
and EOS in the development of obesity, in order to identify
disease biomarkers and disclose new molecular clues to be
targeted by innovative strategies of pharmacological intervention.
By using a well-established rat model of Diet-Induced Obesity
(DIO), we first investigated regulation of ECS and EOS genes
expression during disease progression in the hypothalamus,
a brain region involved in appetite regulation (Bazhan and
Zelena, 2013), where the role of ECS (Berthoud, 2012; Zeltser
et al., 2012; Ramírez-López et al., 2015) and EOC (Dum et al.,
1983; Nogueiras et al., 2012; Romero-Picó et al., 2018) in
feeding response modulation has been deeply investigated and
already reported. We followed gene expression regulation at the
beginning of obesity development (i.e., after 5 weeks on high
fat diet), as well as when the phenotype was well-established
(i.e., after 21 weeks on high fat diet). Among the epigenetic
mechanisms possibly responsible for altered gene expression, we
focused on DNA methylation, that consists of a methyl group
transfer to the position 5 of the cytosine pyrimidine ring in a
cytosine guanine dinucleotide (CpG), which ultimately blocks
the binding of transcription factors thus causing chromatin
compaction and gene silencing (Zhu et al., 2016). Of note, by
using the same DIO animal model considered here, we already
showed the epigenetic regulation of other obesity genes in the
progression of the disorder (Cifani et al., 2015).
In addition, in this work, we also analyzed the DNA
methylation status of key ECS and EOS genes in peripheral
blood mononuclear cells (PBMCs) from a subset of humans with
obesity. It is important to recall that PBMCs contain the complete
epigenetic machinery present in neurons (Arosio et al., 2014),
and are considered a convenient substitute for cerebral markers
(Woelk et al., 2011) that are readily accessible and reflects the
molecular processes occurring in the central nervous system
(Gladkevich et al., 2004). PBMCs have been already proposed in
obesity studies as a valuable tool to monitor metabolic recovery
in weight loss strategies (Reynés et al., 2015), and thus their study
in this disorder is of clear relevance to detect altered pathways
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(metabolic or signaling) that could be transferred to the brain.
Moreover, it has been well-documented since many years the
activation of the ECS in human obese subjects and the regulation
of EOS components in obesity and related eating disorders in the
periphery (Jimerson and Wolfe, 2004).
MATERIALS AND METHODS
Animals and Diet Composition
Male Sprague Dawley rats (Charles River; total n = 38; 225–250 g,
7 weeks old at the beginning of the experiments) were used. Rats
were housed in individual cage sunder 12:12 h light/dark cycle
(lights on at 9:00 a.m.) with access to food and water ad libitum
for 2 weeks before the experiments. They were kept in a room
at constant temperature (20–22◦C) and humidity (45–55%). All
procedures involving rats were carried out in accordance with the
Institutional Guidelines and complied with the Italian Ministry of
Health and associated guidelines from European Communities
Council Directive. Rats were randomly divided into two groups
with comparable mean body weight (no significant difference).
The first group (n = 16) was the control group and was fed with
standard laboratory chow ad libitum (4RF18, Mucedola, Settimo
Milanese, Italy; 2.6 kcal/g); the second group (n = 22), was fed
with high energy diet (45% fat, 35% Carbohydrate, 20% Protein)
ad libitum (D12451, Research Diets, Inc., New Brunswick, NJ,
United States; 5.24 kcal/g). After 5 weeks, 6 of the 22 rats fed
with high fat diet did not significantly increase body weight
in comparison to rats fed with chow. These resistant rats were
excluded from the study (Cifani et al., 2015) because they did
not develop obese phenotype. At the end of the 5 weeks, eight
Chow and eight DIO rats were sacrificed by decapitation. The
remaining animals (additional eight Chow and eight DIO rats)
were maintained on their respective diets for 21 weeks, and
then were sacrificed. Brains were quickly removed and the whole
hypothalamus was manually dissected (from Bregma level −0.26
to Bregma level −4.20) (Paxinos and Watson, 1998). The tissues
were collected and stored at −80◦C until further analysis. Body
weight and food intake were daily recorded (Figure 1).
Human Subjects
Patients and Methods
Editorial policies and ethical considerations
The study, accomplishing the Declaration of Helsinki, was
approved by the Ethic Committee of IRCCS – Istituto Auxologico
Italiano (RBFR12DELS_004/05C302_2013), and all patients or
their tutors gave a written informed consent.
Study population
The entire cohort consists of 63 humans with obesity recruited
from the San Giuseppe Hospital’s and San Luca Hospital’s
(Istituto Auxologico Italiano) since 2012. Clinical characteristics
of our cohort are reported in Table 1. Anonymous patient
data, referred to the time of diagnosis, were collected either
prospectively or retrospectively and a clinical database was
created. We performed the same epigenetic analysis in 58
non-obese blood donors matching for age and sex (Males:
No. = 32, age = 42.27± 2.97; Females: No. = 26, age 40.87± 4.12).
Data collection
In this study all humans with obesity had physical examination
and biochemistry analyses. To perform the body weight and
height measurements, subjects were dressed in light clothing
without socks and shoes. Weight was measured (in kg to two
decimal places) with a digital balance scale. Height was mea-
sured with a wall-mounted stadiometer (to the nearest milli-
meter) using the stretch technique. Body mass index (BMI) was
calculated using the Quetelet’s formula as weight (in kg) divided
by height (in m2). Systolic (SBP) and diastolic (DBP) blood
pressure were measured in the seated position with a Tema
Certus sphygmomanometer and an appropriately sized cuff on
the right arm. These values were obtained as the average of three
measurements. Blood samples were separated by centrifugation
after clotting, and aliquots of serum or plasma supernatants were
processed for routine measurements and stored at −80◦C until
assay. Routine laboratory data included levels of glucose, total cho-
lesterol, high-density (HDL) and low-density lipoprotein (LDL)
cholesterol, triglycerides (TG) determined by enzymatic assays
(Roche Diagnostics GmbH, Mannheim, Germany). Anthropo-
metrical and biochemical measurements were made once for
each participant. According to the World Health Organization
guidelines, obesity was defined as BMI≥ 30 kg/m2 (WHO, 2000).
Non-obese blood donors were selected in accordance with
National mandatory standards for blood donor selection. They
were known to be free from chronic disease (including diabetes,
hypertension, dyslipidemia, and cardiovascular disease), not
taking any drugs and with BMI < 29.9 kg/m2.
Molecular Biology Studies
Real-Time Quantitative PCR
Total RNA was isolated using TRIzol reagent (Thermo Fisher
Scientific) according to the specifications of the instructions,
from rat dissected Hypothalamus and from PBMCs, separated
by density gradient using the Lympholyte-H kit (Cedarlane
Laboratories, Canada). Each 0.5 µg of total RNA was reverse-
transcribed into complementary DNA using a RevertAid
RT Reverse Transcription Kit (Thermo Scientific). Random
hexamers and oligo-dT primers were used in the RT reaction
in an unbiased manner Quantitative PCR was performed
using an Applied Biosystems 7500 Real-time PCR system
(Thermo Fisher Scientific) with SensiFAST SYBR Low-ROX kit
(Bioline) in a total reaction volume of 10 µl according to the
manufacturer’s instructions. The thermal cycles were as follows:
initial denaturation at 95◦C for 2 min; 45 cycles of denaturation
at 95◦C for 15 s; annealing and extension at 60◦C for 15 s.
Relative mRNA expression levels were calculated using the
2−DDCt method and normalized to two internal control, β-actin
and GAPDH. The primers used for the amplification of ECS and
EOS genes are reported in Supplementary Table S1.
DNA Methylation Analysis by Pyrosequencing
Genomic DNA was extracted from hypothalamic region
and PBMC by using TRIzol Reagent (Life Technologies)
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FIGURE 1 | (A) Body weight and (B) cumulative food intake (kcal) measured weekly in rats exposed for 5 and 21 weeks to high fat (HFD) or standard diet (STD).
Significant differences are indicated: ∗∗∗P < 0.001, ∗P < 0.05 vs. STD.
with the concentration and purity detected by NanoDrop
spectrophotometer (NanoDrop Technologies, United States).
DNA was subjected to bisulfite modification by means of
a commercially available modification kit (Zymo Research).
Pyrosequencing was used to quantify the methylation levels of
individual CpG sites. The sequencing was performed for all the
study samples on a PyroMark Q24 ID using Pyro Mark Gold
reagents (Qiagen). Primers for rat and human CNR1, the gene
coding for the cannabinoid receptor type 1 (CB1) (targeting in
rats eight CpG sites and in humans five CpGs) and OPRM1, the
gene coding for mu opioid receptor (MOP) (targeting in rats four
CpG sites and in humans five CpGs), were generated according
to Pyro Mark Assay Design software version 2.0 (Qiagen). The
schematic representation of CpG island at CNR1 and OPRM1
promoter regions and the details of the pyrosequencing assay are
illustrated in Figure 2 and Supplementary Table S2. Bisulfite
treated DNA was amplified by PyroMark PCR Kit (Qiagen)
according to the manufacturer’s protocol. Polymerase chain
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TABLE 1 | Clinical characteristics and biochemical parameters of subjects
enrolled for the DNA methylation study.
Obese subjects Males Females
No. 27 36
Age, years ± SD 44.15 ± 4.45 41.62 ± 4.135
BMI, kg/m2 ± SD 40.69 ± 1.52 40.23 ± 1.17
Glicemia ± SD 115.30 ± 9.18 98.89 ± 4.29
Cholesterol-total, mg/dL ± SD 172.70 ± 8.74 175.20 ± 7.24
Cholesterol-HDL, mg/dL ± SD 93.85 ± 9.93 104.40 ± 11.98
Cholesterol-LDL, mg/dL ± SD 60.70 ± 6.46 65.47 ± 4.67
Triglycerides, mg/dL ± SD 135.00 ± 11.11 116.80 ± 7.90
Systolic blood pressure, mmHg ± SD 125.20 ± 1.88 123.10 ± 1.25
Diastolic blood pressure, mmHg ± SD 77.22 ± 1.11 78.06 ± 1.34
reaction conditions were as follows: 95◦C for 15 min, followed
by 45 cycles of 94◦C for 30 s, 56◦C for 30 s, 72◦C for 30 s, and
finally, 72◦C for 10 min. Polymerase chain reaction products were
verified by agarose electrophoresis. Pyromark Q24 ID version
1.0.9 software, which generates and automatically analyzes the
resulting pyrograms, was used to calculate the methylation per-
centage mC/(mC+C) (where mC is methylated cytosine and C is
unmethylated cytosine), for each CpG site, allowing quantitative
comparisons. Quantitative methylation results were considered
both as a percentage of individual CpG sites and as an average of
the methylation percentage of the all the investigated CpGs.
Statistical Analysis
All results are expressed as mean ± SEM. Statistical differences
of genes expression and DNA methylation changes at gene
promoters in both human and animal samples were determined
using Prism version 6 (Graph-Pad Software, San Diego, CA,
United States). In behavioral experiments, data were analyzed
by two-way ANOVA with the animal group as the between-
subject variable and time as the within-subject variable followed
by post hoc comparison carried out by the Bonferroni test.
In molecular biology studies, data were analyzed by two-
way ANOVA with the animal group as the between-subject
variable and CpG sites as the within-subject variable. Significant
differences induced by diet were analyzed using the Mann–
Whitney U test. DNA methylation at each CpG site was analyzed
using the Mann–Whitney test and Sidak–Bonferroni correction
was used for the multiple comparisons. The P-values< 0.05 were
considered to be statistically significant.
RESULTS
High Fat Diet Effect on Body
Weight and Food Intake
At the beginning of the study, body weight of rats in the high fat
diet group (278.3 ± 7.0 g) did not differ significantly from that
of the rats in the control group (286.2 ± 6.3 g) [F(1,30) = 0.7;
P > 0.05]. At the end of the fifth week, two-way ANOVA
showed a significant difference in body weight between the
groups (Diet: [F(1,30) = 7.2; P < 0.05]; Time: [F(4,120) = 297.5;
P < 0.01]; Interaction: [F(4,120) = 6.7; P < 0.01]). At the fifth
week time point, post hoc test showed that body weight of DIO
rats began to be significantly higher compared to that of control
group (P < 0.05).
At the end of the 21st week, two-way ANOVA showed a
significant difference in body weight between the groups (Diet:
[F(1,14) = 10.0; P < 0.01]; Time: [F(20,280) = 230.2; P < 0.001];
Interaction: [F(20,280) = 5.3; P < 0.001]). At the same time
point (21st week) of free access to high fat diet, post hoc test
FIGURE 2 | Schematic representation of rat and human Cnr1 and Oprm1 genes. Position of transcription start site (TSS), translation start code (ATG), exons and
introns, CpG island are depicted. Details of the sequences under study for DNA methylation are shown in Supplementary Table S2.
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FIGURE 3 | Cnr1 and Oprm1 transcriptional regulation. Cnr1 relative gene expression (A) and DNA methylation at gene promoter (B) and Oprm1 relative gene
expression (C), and DNA methylation at gene promoter (D) analyzed in the hypothalamus of rats exposed for 5 and 21 HFD and/or STD Gene expression data are
reported as 2-DDCt values calculated by Delta–Delta Ct (DDCt) method vs. STD (5 weeks) posed equal to 1. DNA methylation data are presented as the mean of the
methylation % values of individual CpG sites under study as well as of the average (Ave) of the eight CpG sites ± SEM. ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05 vs.
STD.
showed that body weight of DIO rats was significantly higher
in comparison to body weight of rats fed with standard diet
(591.0± 2.2 g) (P < 0.001; Figure 1A).
Overall ANOVA showed a significant difference in energy
intake (kcal/kg) between the groups in the first 5 weeks (Diet:
[F(1,30) = 110.9; P < 0.001]; Time: [F(4,120) = 117.7; P < 0.001];
Interaction: [F(4,120) = 29.8; P < 0.001]). At the end of the 21st
week, two-way ANOVA showed a significant interaction between
diet and time [F(4,120) = 29.9; P < 0.001]. Significant differences
at each time point are shown in Figure 1B. Open field test
showed significant difference between the groups in Distance
travel, Vertical count, Grooming and Zone Entries only after 21
weeks of diet exposure (Supplementary Table S3).
Regulation of ECS and EOS Genes
Transcription in the Hypothalamus
ECS
In addition to CB1, endocannabinoid signaling is based on
a rather complex array of proteins that form the so-called
ECS. These include additional receptor targets, like type-2
cannabinoid receptor (CB2) and transient receptor potential
vanilloid-1 (TRPV1) channels, and metabolic enzymes involved
in biosynthesis and degradation of endocannabinoids (Chiurchiù
et al., 2018). All these elements of ECS were analyzed by qRT-PCR
(Figure 3 and Table 2).
After 5 and 21 weeks, statistical analysis showed no
significant changes of ECS elements, except for Cnr1, the
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TABLE 2 | Gene expression of ECS and EOS elements in the hypothalamus of
normal weight and overweight rats exposed for 5 and 21 weeks to high fat and/or
standard diet, reported as 2−DDCt values calculated by Delta–Delta Ct (DDCt)
method vs. normal weight (5 weeks) posed equal to 1.
HYP 5 weeks 21 weeks
Gene STD HFD STD HFD
ECS Cnr1 1.03 ± 0.03 1.42 ± 0.09a 0.79 ± 0.07 1.18 ± 0.16c
Cnr2 1.21 ± 0.25 1.16 ± 0.70 1.98 ± 0.57 1.90 ± 0.59
Gpr55 1.22 ± 0.29 1.10 ± 0.21 1.44 ± 0.14 1.54 ± 0.27
Trpv1 1.24 ± 0.30 1.34 ± 0.45 1.22 ± 0.29 0.78 ± 0.06
Nape-Pld 1.06 ± 0.10 1.08 ± 0.15 1.10 ± 0.13 1.08 ± 0.18
Faah 1.09 ± 0.17 0.87 ± 0.12 1.36 ± 0.12 1.48 ± 0.10
Dagl 1.05 ± 0.13 1.49 ± 0.26 0.74 ± 0.07 0.58 ± 0.05
Magl 1.04 ± 0.11 1.14 ± 0.14 0.94 ± 0.08 0.88 ± 0.13
Opiod Oprl1 0.98 ± 0.05 1.23 ± 0.08 1.11 ± 0.12 1.15 ± 0.02
system
Oprm1 1.03 ± 0.09 1.84 ± 0.26b 1.03 ± 0.17 1.10 ± 0.22
Oprd1 1.03 ± 0.11 1.36 ± 0.22 0.73 ± 0.09 0.71 ± 0.07
Oprk1 1.05 ± 0.17 1.23 ± 0.30 1.29 ± 0.23 1.19 ± 0.30
Pomc 1.18 ± 0.33 0.89 ± 0.22 1.19 ± 0.30 0.73 ± 1.19
Pnoc 1.03 ± 0.10 1.48 ± 0.17 1.00 ± 0.13 0.89 ± 0.11
Pdyn 1.04 ± 0.11 1.30 ± 0.23 1.02 ± 0.12 0.97 ± 0.08
Penk 1.01 ± 0.04 0.99 ± 0.15 1.06 ± 0.13 1.15 ± 0.17
ap < 0.05 vs. STD; bp < 0.01 vs. STD; cp < 0.001 vs. STD.
TABLE 3 | DNA methylation changes at Cnr1 gene promoter in the hypothalamus
of normal weight and overweight rats exposed for 5 weeks to high fat
and/or standard diet.
Cnr1 5 weeks 21 weeks
CpG sites STD HFD STD HFD
1 4.55 ± 0.48 4.24 ± 0.42 5.11 ± 0.31 5.28 ± 0.67
2 4.76 ± 0.64 2.30 ± 0.28b 5.49 ± 0.63 4.64 ± 0.29
3 3.37 ± 0.45 1.37 ± 0.10c 3.83 ± 0.35 2.77 ± 0.26
4 6.36 ± 0.87 3.81 ± 0.28a 8.17 ± 0.73 6.15 ± 028
5 1.31 ± 0.21 1.01 ± 0.20 1.69 ± 0.14 1.43 ± 0.18
6 2.22 ± 0.23 1.69 ± 0.13 2.35 ± 0.25 2.14 ± 0.20
7 3.13 ± 0.45 2.23 ± 0.28 3.64 ± 0.29 2.67 ± 0.28
8 3.77 ± 0.35 2.60 ± 0.25a 4.30 ± 0.48 3.21 ± 0.23
Average 3.72 ± 0.43 2.46 ± 0.11a 4.33 ± 0.32 3.54 ± 0.17
ap < 0.05 vs. STD; bp < 0.01 vs. STD; cp < 0.001 vs. STD.
gene encoding for CB1 (Table 2). Two-way ANOVA showed
that mRNA levels were affected by time [F(1,25) = 10.50,
P = 0.003] and diet [F(1,25) = 20.72, P = 0.0001], without a
significant interaction between these two factors [F(1,25) = 0.27,
P = 0.607]. T-test revealed a selective and significant increase
in Cnr1 mRNA levels in HFD rats with respect to STD
animals at both time points analyzed (5 weeks = P < 0.0006;
21 weeks = P < 0.036; Figure 3A).
DNA methylation analysis of each CpG site, and as an average
of all eight CpG sites analyzed at the Cnr1 promoter, showed
significant changes in rats after 5 weeks on high fat diet (t-test:
P = < 0.006; Figure 3B and Table 3). Two-way ANOVA showed
that DNA methylation was affected by time [F(1,26) = 6.62,
P = 0.016] and diet [F(1,26) = 5.34, P = 0.029], without a significant
interaction between these two factors [F(1,26) = 0.024, P = 0.876].
Moreover, a t-test corrected by Sidak–Bonferroni multiple
comparisons indicated a significant decrease of Cnr1 methylation
levels at sites 2, 3, 4, and 8, as well as in the average of the eight
sites analyzed, when compared to the STD group. No changes
in DNA methylation were observed after 21 weeks (Table 3 and
Figure 3B). Consistently, a correlation between gene expression
and average DNA methylation was also observed in overweight
and normal weight animals after 5 weeks of diet (Spearman
r = 0.609; P = 0.018; Figure 4A), but not after 21 weeks (Spearman
r = 0.316; P = 0.271; Figure 4B).
EOS
EOS consists of four receptors, mu (OPRM1), delta (OPRD1),
kappa (OPRK1), and Opioid related nociceptin receptor 1
(OPRL1) which are activated by endogenous opioid peptides
processed from four protein precursors, proopiomelanocortin
(POMC), proenkephalin (PENK), prodynorphin (PDYN) and
pronociceptin (PNOC) (Corbett et al., 2006; Bodnar, 2010).
Among EOS elements, only the expression of genes encoding
for the receptors Oprm1 and Oprd1 were altered (Figure 3
and Table 4). Two-way ANOVA showed that Oprm1 mRNA
levels were affected by diet [F(1,25) = 4.90, P = 0.036] but
not by time [F(1,25) = 3.45, P = 0.07], and there was no
significant interaction between these two factors [F(1,25) = 3.43,
P = 0.07]. T-test revealed a selective and significant increase
in Oprm1 mRNA levels in rats after 5 weeks on high fat
diet with respect to STD animals (5 weeks = P < 0.05;
Figure 3C and Table 4).
DNA methylation analysis of each CpG site, and as an average
of all four CpG sites analyzed at the Oprm1 promoter, did not
show any significant change in rats exposed for 5 and 21 weeks
to high fat diet (Table 4 and Figure 3D), nor any correlation
between gene expression and average DNA methylation (at
5 weeks: Spearman r =−0.001; P = 0.961; at 21 weeks: Spearman
r =−0.304; P = 0.282; Figures 4C,D).
DNA Methylation at CNR1 and OPRM1
Promoter Regions in Clinical Samples
We sought to extend the analysis of DNA methylation at CNR1
and OPRM1 promoters in the preclinical animal model to a
group of humans with obesity and matched healthy controls
(CTRLs). In these samples, we failed to observe any alteration
of the epigenetic hallmark at both gene promoters in the overall
population (Table 5). Yet, data stratification based on subject
age showed significant differences at both gene promoters in
individuals younger than 30 years (Figure 5). Namely, DNA
methylation at CNR1 promoter was lower in humans with
obesity at CpG 5 (CTRLs = 2.62 ± 0.17, obese = 2.16 ± 0.06;
p = 0.006), as well as at the average of the five CpG sites under
study (CTRLs = 4.97± 0.11, obese = 5.58± 0.10; p = 0.008), when
compared to age-matched controls (Figure 5A). Instead, DNA
methylation at OPRM1 promoter was significantly lower in obese
subjects at CpG 1 (CTRLs = 6.57 ± 0.31, obese = 5.28 ± 0.30;
p < 0.01), CpG 2 (CTRLs = 12.37 ± 0.44, obese = 9.85 ± 0.40;
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FIGURE 4 | Correlation between Cnr1 expression and % change of DNA methylation after 5 (A) and 21 weeks of diet (B). Correlation between Oprm1 expression
and % change of DNA methylation after 5 (C) and 21 weeks of diet (D). Data were analyzed by Spearman’s rank correlation coefficient.
p < 0.001), CpG 3 (CTRLs = 11.10 ± 0.76, obese = 8.31 ± 0.27;
p< 0.001) and CpG 4 (CTRLs = 8.22± 0.47, obese = 6.61± 0.25;
p < 0.01), when compared to age-matched controls (Figure 5A)
No differences in DNA methylation were observed between
TABLE 4 | DNA methylation changes at Oprm1 gene promoter in the
hypothalamus of normal weight and overweight rats exposed for 5 and 21 weeks
to high fat and/or standard diet.
Oprm1 5 weeks 21 weeks
CpG sites STD HFD STD HFD
1 3.56 ± 0.62 4.16 ± 0.40 3.05 ± 1.14 4.64 ± 1.00
2 7. 30 ± 1.13 8.55 ± 0.57 8. 05 ± 1.16 7.31 ± 0.52
3 2. 81 ± 0.45 2.92 ± 0.67 3. 38 ± 0.59 5.15 ± 1.40
4 3.46 ± 0.43 3.54 ± 0.34 3.90 ± 0.68 4.82 ± 1.12
Average 4.28 ± 0.64 4.80 ± 0.44 4.60 ± 0.75 7.04 ± 1.72
obese and healthy controls in subjects older than 30 years
(Figure 5B). We also observed the DNA methylation levels on
CNR1 and OPRM1 gene promoters in humans with obesity
and Ctrl stratified for gender (Supplementary Figure S1).
TABLE 5 | DNA methylation changes at human CNR1 and OPRM1 gene
promoters in controls (CTRL) and humans with obesity.
Gene CNR1 OPRM1
CpG sites CTRL Obese CTRL Obese
1 2.36 ± 0.14 2.27 ± 0.07 7.87 ± 0.37 7.11 ± 0.32
2 10.41 ± 0.28 10.39 ± 0.25 15.62 ± 1.20 14.76 ± 0.83
3 5.84 ± 0.24 5.72 ± 0.15 12.90 ± 0.56 12.04 ± 0.57
4 3.03 ± 0.22 2.93 ± 0.10 9.55 ± 0.38 9.03 ± 0.43
5 2.70 ± 0.13 2.52 ± 0.09 7.65 ± 0.35 8.03 ± 0.95
Average 4.87 ± 0.17 4.74 ± 0.13 10.72 ± 0.50 10.19 ± 0.47
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FIGURE 5 | Comparison of DNA methylation status at human CNR1 (A,C) and OPRM1 (B,D) promoters in the obese population and control (CTRL) subjects
stratified based on age (A,B = < 30 years old; C,D > 30 years old). The bars represent the mean of the % of methylation values of individual CpG sites under study
as well as of the average (ave) of the CpG sites ± the SEM. Significant differences are indicated: ∗∗P < 0.01; ∗∗∗P < 0.001 vs. CTRL.
No differences in the % of DNA methylation of CNR1
were observed in female and male subjects (Supplementary
Figures S1A,B). Lower levels in DNA methylation at OPMR1
were observed in human males with obesity at CpG site 3
(CTRLs = 13.45 ± 0.65, obese = 10.13 ± 0.79, P < 0.004), CpG
site 4 (CTRLs = 9.94 ± 0.45, obese = 7.61 ± 0.52, P < 0.003),
as well as at the average of the five CpG sites under study
(CTRLs = 10.96 ± 0.49, obese = 8.72 ± 0.64, P < 0.010),
when compared to CTRLs (Supplementary Figure S1A). No
differences in the % of DNA methylation of OPRM1 were
observed in female subjects (Supplementary Figure S1B).
Considering just the humans with obesity, DNA methylation
differences were not observed after data stratification based
on gender (Supplementary Figure S2). Focusing on the obese
population only, DNA methylation differences were observed
after data stratification based on the time length from obesity
onset (Figure 6). Additionally, methylation at CNR1 promoter of
subjects that were obese for more than 5 years was higher than
that of humans with obesity for a shorter time. In particular, we
observed a significant increase at two of the five sites analyzed,
namely at the second (CTRLs = 9.78± 0.23, obese = 11.32± 0.37;
p < 0.008) and at the fifth (CTRLs = 2.23 ± 0.06, obese =
2.80 ± 0.13; p < 0.14) CpG site, respectively (Figure 6A).
Methylation of the combined five CpG sites analyzed in the
promoter region of OPRM1 showed a significant increase in DNA
methylation of humans with obesity for a long time (>5 years
from onset) (CTRLs = 7.36 ± 0.51, obese = 11.51 ± 0.95;
p < 0.001). Moreover, we observed a significant increase in the
first (CTRLs = 4.91 ± 0.24, obese = 7.73 ± 0.50; p < 0.001),
second (CTRLs = 9.49 ± 0.34, obese = 18.18 ± 2.23; p < 0.001),
third (CTRLs = 8.00 ± 0.21, obese = 13.42 ± 0.73; p < 0.001),
and fourth (CTRLs = 6.45 ± 0.25, obese = 10.50 ± 1.01;
p < 0.001) CpG site analyzed (Figure 6B). Finally, differences
were also observed when considering the BMI of humans
with obesity, and post hoc group differences are reported in
Supplementary Figure S3. Focusing on humans with obesity
younger than 30 years, we compared the DNA methylation
status at CNR1 and OPRM1 promoters in Preadolescents
(8–12 years old), Adolescents (13–17), Young adults (18–30)
(Supplementary Figure S4). A t-test corrected by Sidak–
Bonferroni multiple comparisons indicated a significant increase
of OPRM1 methylation levels at CPG site 3 of young adults,
when compared to the adolescents (Adolescent = 7.96 ± 0.26,
Young adult = 9.85 ± 0.78, P < 0.008). Association remained
for all stratified data, after Sidak–Bonferroni correction for
multiple testing.
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FIGURE 6 | Comparison of the DNA methylation status at human CNR1 (A) and OPRM1 (B) promoters in the obese population stratified based on the years from
obesity onset. The bars represent the mean of the % of methylation values of individual CpG sites under study as well as of the average (ave) of the CpG sites ± the
SEM. Significant differences are indicated: ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 vs. obese > 5.
DISCUSSION
The first outcome of this study is the selective up-regulation
of the expression of Cnr1, the gene coding for CB1, and of
Oprm1, the gene coding for MOP, in the hypothalamus of rats
exposed to high fat diet for 5 and 21 weeks. These alterations
were present at both time-points analyzed for CB1, that appeared
to be engaged in long-lasting effects, and only at the beginning
of obesity development for MOP, that appeared to be engaged in
obesity onset only. Of note, we failed to observe any alteration
in any other component of the ECS and of the EOS, speaking in
favor of a distinct role of the two receptors in obesity.
Our data are thus consistent with many studies that already
showed the hyperphagic role of CB1 (Williams and Kirkham,
1999; Jamshidi and Taylor, 2001; Verty et al., 2005; Koch
et al., 2015) and MOP (Smith et al., 2002) in this brain
region. Hypothalamic administration of the endocannabinoid
anandamide (Jamshidi and Taylor, 2001) or of the cannabis
extract tetrahydrocannabinol (THC) (Verty et al., 2005), both
primarily acting though CB1 in the brain, rapidly increases food
intake in rats. Studies focused on the hypothalamus documented
also that high-fat feeding increases MOP protein levels in Wistar
rats (Smith et al., 2002), as well as in rats susceptible to obesity
(Barnes et al., 2006).
The link between these two receptors in the promotion of
feeding has been proposed by Kock and colleagues, who showed
that this effect can be due to CB1 activation on POMC neurons
leading to the release of β-endorphin, an opioid neuropeptide
acting on MOP (Koch et al., 2015).
Despite the great amount of research showing CB1 levels
dysregulation centrally in animal models of obesity (South and
Huang, 2008; Massa et al., 2010), there is less information
about altered hypothalamic Cnr1 mRNA levels, which anyhow
have been reported by some (Kempf et al., 2007; Gamelin
et al., 2016; Ramirez-Lopez et al., 2016). Consistently with
our present findings, Cnr1 mRNA levels increased in female
offspring hypothalami from rat dams fed a high caloric diet
(Ramirez-Lopez et al., 2016). Moreover, receptor knockdown in
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mice hypothalamus induced a reduction in body weight while
increasing energy expenditure (Cardinal et al., 2012). On the
other hand, receptor gene expression was down-regulated in
the hypothalamus of rats fed with a palatable high-energy diet
(Timofeeva et al., 2009). It seems noteworthy that in a recent
analysis of the transcriptional regulation of ECS components
in an animal model of binge eating behavior, we observed a
selective epigenetic regulation of fatty acid amide hydrolase, the
key enzyme for the degradation of anandamide, instead,Cnr1 and
all other ECS components were not affected (Pucci et al., 2018).
This seems of particular relevance if one aims at finding specific
biomarkers for different eating disorders and related disturbances
(such as obesity).
The involvement of MOP gene regulation in obesity has also
been investigated. MOP KO mice fed a high-fat diet were resistant
to obesity (Tabarin et al., 2005), even though others also showed
that MOP KO mice on a standard diet increased body weight
in adulthood, when compared to wild-type littermates (Han
et al., 2006). Analysis of gene expression showed increased MOP
mRNA levels in hypohalami of the offspring of obese pregnant
mice (Vucetic et al., 2010; Grissom et al., 2014), whereas no
changes were observed in mice fed from weaning with high-fat
diet for around 15 weeks (Vucetic et al., 2011).
In order to characterize MOP and CB1 transcriptional
regulation, we sought to compare hypothalamic genes DNA
methylation. We observed a consistent reduction of the
epigenetic hallmark at Cnr1 promoter, in four of the eight CpG
sites under study as well as in their methylation average, but only
at the earliest time-point (5 weeks). However, no changes were
observed in MOP DNA methylation. These findings suggest that
the temporary hypomethylation at Cnr1 gene at the beginning of
obesity development might be responsible of the early changes
observed in gene expression; yet, it does not seem necessary in
the long term, when chromatin might be in a poised state with
mRNA levels resulting still high. At any rate, this is the first
report showing DNA methylation of Cnr1 in obesity, whereas
others have already addressed MOP epigenetic regulation in
mice reward-related brain regions of the offspring of pregnant
dams exposed to chronic high-fat diet (Vucetic et al., 2011). In
partial agreement with our data, also the latter studies failed to
show alterations of methyl CpG-binding protein, as well as of
histone acetylation, at MOP gene promoter in the hypothalamus
(Vucetic et al., 2011). Very recently the hypothalamic increase in
histone acetylation was instead reported at Cnr1 gene promoter,
and was linked to increased hypothalamic receptor expression
(Almeida et al., 2019).
With the aim to extend the study of CB1 and MOP receptors to
human obesity, we assessed whether PBMCs might mirror central
nervous system defects, and we then evaluated DNA methylation
at CNR1 and OPRM1 gene promoters in PBMCs of humans with
obesity. We failed to observe any difference between controls
and humans with obesity in the overall population, yet age-based
stratification of the data clearly showed a significant reduction
of the epigenetic hallmark at both CNR1 and OPRM1 promoters
in younger (<30 years old) humans with obesity. As for CNR1,
an age-dependent modulation was observed at one of the five
CpG sites analyzed, as well as at their average, possibly driving an
up-regulation of gene expression compared with normal weight
subjects. Instead, in the same population DNA methylation was
reduced in four of the five CpG sites analyzed. These differences
for both receptors did not occur in subjects older than 30 years.
Our findings appear of particular relevance if one attempts to
identify early disease biomarkers. In agreement with this, a
lower DNA methylation was also observed at genes promoters
of humans with obesity with a shorter time length from disorder
onset, and in those with lower BMI.
At the clinical level, it seems noteworthy that an increased
CNR1 expression in obesity has been shown at the peripheral
level (Pagano et al., 2007; Sarzani et al., 2009), but never in
blood samples from human subjects. Moreover, to the best of
our knowledge, OPRM1 expression in humans with obesity has
not been studied yet, with the only available PET clinical study in
different brain regions reporting lower MOP availability in obese
subjects compared to controls (Karlsson et al., 2015).
Overall, our findings in human peripheral samples confirm
the data observed centrally in the animal model, showing that
regulation of CNR1 and OPRM1 genes is altered mainly at the
early stage of phenotype development, at least in terms of the
epigenetic hallmarks analyzed.
CONCLUSION
In conclusion, epigenetic switching appears dynamic and
temporary in the preclinical and clinical models used here to
investigate CNR1 and OPRM1. Alterations of DNA methylation
in these two genes, observed earlier in the obese phenotype as
a result of early exposure (i.e., to high-fat diet or, for instance,
to stressful conditions), disappear at a later stage in life. Thus,
here we clearly show the relevant role of CNR1 and OPRM1
transcriptional regulation as a possible biomarker for obesity and,
due to the reversible nature of the epigenetic hallmark, our data
open new avenue for environmental strategies of intervention.
As yet, conventional environmental strategies for the treatment
of obesity include lifestyle modifications of diet and physical
activity, and are often insufficient (Blevins, 2010). However, this
might be also due to the lack of an early diagnosis. In line with
this, our data support the relevance of a preventive therapeutic
approach based on environmental factors.
Of relevance, a very recent study has reported altered DNA
methylation on obesity-related genes in healthy adolescents,
and these alterations were suggested as early life changes
possibly associated with elevated disease risk in adulthood
(He et al., 2019).
Study Limitations
We should point out that we analyzed PBMCs, composed of
different cell types with different DNA methylation profiles
(Bell et al., 2011). However, in order to extract homogeneous
populations, cell manipulation is required, which is a laborious
and difficult procedure to standardize, possibly affecting gene
expression profiles (Whitney et al., 2003; Debey et al., 2004).
Therefore, laser capture micro-dissected tissues might be used
to address this issue in future studies. Moreover, for a better
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understanding of the relationship between blood and brain in
terms of epigenetic modulation, it would be of interest to study
also in rats transcriptional regulation of genes in blood. In
addition, it seems necessary to extend the present study to a
larger cohort of human subjects, possibly by using innovative
methods to achieve cell-sorting, and to add different preclinical
experimental models of obesity to further characterize the
epigenetic regulation of CNR1 and OPRM1 expression, as well as
the relationship between their peripheral and central modulation.
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